Thymosin Alpha-1 Guide — What It Is, How It Works & What the Research Shows

What it is

Thymosin alpha-1 (Tα1) is a small 28-amino-acid peptide that your body makes naturally. It's produced by the thymus, a small gland behind the breastbone that acts as a training school for the immune system's T-cells. Tα1 is one of several signaling molecules the thymus releases to help coordinate immune defenses.

A synthetic (lab-made) copy of this natural peptide is manufactured as the prescription drug thymalfasin, sold under the brand name Zadaxin. Zadaxin is approved and marketed in more than 35 countries — including China, Italy, and others — mainly for chronic hepatitis B and C and as an immune booster.

In the United States, thymosin alpha-1 has never been approved by the FDA as a marketed drug. It has held orphan-drug designations for certain conditions, but that is a research incentive, not marketing approval. US access is through compounding pharmacies or the unapproved research 'grey market.'

How it works

Tα1 acts as an immune tuner rather than a simple stimulant. It helps immature immune cells in the thymus mature into working T-cells (CD4+ and CD8+), and it activates dendritic cells — the 'scout' cells that show the immune system what to attack. It also nudges the body to make more infection-fighting signals like interferon and interleukin-2. Much of this is thought to work through a receptor called TLR9.

Uniquely, Tα1 appears to work in both directions: it can ramp immune activity up when defenses are weak (as in chronic infection), and help calm an over-reacting immune system by boosting regulatory T-cells and anti-inflammatory signals like IL-10. This 'balancing' effect is why researchers have studied it in both infections and inflammatory conditions like sepsis.

What people research it for

Chronic hepatitis B and C support

Human studies

Its most established use. In controlled trials, Tα1 (often alongside interferon) improved viral and liver-enzyme responses in chronic viral hepatitis — the basis for Zadaxin's approval abroad. Note: modern direct-acting antivirals have largely superseded this role.

Immune support in weakened patients

Early human data

Used abroad as an immune adjuvant — for example, to strengthen response to vaccines or in people with impaired immunity, such as some cancer or dialysis patients.

Severe sepsis outcomes

Early human data

In the ETASS randomized trial, Tα1 was linked to a 9-percentage-point drop in 28-day mortality (26% vs 35%), though the result was only borderline statistically significant and larger trials have been mixed.

COVID-19 and post-viral immune recovery

Early human data

Studied during COVID-19 to calm cytokine storms and restore T-cell counts. Some Chinese studies suggested benefit in severe cases, but results overall were inconsistent.

What the research actually shows

Thymosin alpha-1 has far more human trial data than most 'research peptides.' Its strongest evidence is in chronic hepatitis B and C, where randomized trials — usually combining Tα1 with interferon — showed improved viral and liver-enzyme responses. This work underpins Zadaxin's approval in 35+ countries. In practice, though, newer direct-acting antivirals have made this use largely obsolete.

In sepsis, the ETASS trial hinted at lower 28-day mortality, but the finding was borderline (p≈0.06) and a much larger multicenter trial (TESTS, ~1,100 patients) found no clear mortality benefit overall, with only possible signals in elderly or diabetic subgroups. During COVID-19, Tα1 was tested to reduce cytokine storms and rebuild depleted T-cells; some studies were encouraging while others showed no restoration of CD4+/CD8+ counts.

The honest bottom line: Tα1 is a real, well-studied drug abroad with decades of data, but its benefits outside hepatitis are unproven and the trials are mixed. Much of the popular 'immune-boosting' and anti-aging framing goes well beyond what the evidence supports.

Research handling & storage

Thymosin alpha-1 is typically supplied as a lyophilized (freeze-dried) white powder in a sealed vial, which must be reconstituted before use. The pharmaceutical product Zadaxin is given by subcutaneous (under-the-skin) injection after mixing with sterile diluent. Research-grade vials sold in the US grey market are not quality-controlled and may not match label claims.

Freeze-dried powder is generally stored refrigerated and kept away from light; once reconstituted, the solution is refrigerated and used within a limited window. Any handling described here is research/laboratory context only — it is not medical guidance, and no dosing instructions are provided.

Safety & cautions

Across its many human trials, thymosin alpha-1 has a reassuring tolerability record. The most common issue is mild, transient injection-site reactions such as redness or discomfort. Because it modulates the immune system rather than acting as a broad stimulant, serious adverse events have been uncommon in studies, though occasional fever, fatigue, or muscle aches were reported, mostly with interferon combinations.

The important caveat: the US 'research' version is not FDA-approved and is not manufactured to pharmaceutical standards, so purity, sterility, and dosing cannot be assured. Anyone considering immune-modulating therapy — especially people with autoimmune disease, transplants, or cancer — should only do so under a licensed physician, not via grey-market products. This page is educational, not a prescription.

💰

PRICE ALERTS

Track Thymosin Alpha-1 prices

Get an alert when a trusted, tested vendor drops the price. Free.

Frequently asked questions

Is thymosin alpha-1 FDA approved?

No. It is approved and sold as the prescription drug Zadaxin (thymalfasin) in more than 35 countries, but it has never received FDA approval as a marketed drug in the United States. US access is via compounding pharmacies or the unapproved grey market.

What is it used for?

Abroad, its main approved uses are chronic hepatitis B and C and as an immune adjuvant (for example, to boost vaccine response or support weakened immune systems). It has also been studied in sepsis and COVID-19 with mixed results.

Is it the same as thymosin beta-4 (TB-500)?

No. Despite similar names, they are different peptides with different roles. Thymosin alpha-1 mainly modulates the immune system, while thymosin beta-4 is studied for tissue repair and wound healing.

How strong is the evidence compared to other peptides?

Stronger than most. Tα1 has decades of real human clinical trials, especially in hepatitis. But outside hepatitis, results in sepsis and COVID-19 have been inconsistent, and many popular 'immune boosting' claims go beyond the data.

Is it safe?

In clinical trials it has been generally well tolerated, with mostly mild injection-site reactions. However, the US research-grade product is unregulated, and immune-modulating drugs carry real risks for certain people — use only under a qualified physician.

Sources

Last reviewed 2026-07-07. This guide is educational and research-focused — not medical advice. Thymosin Alpha-1 products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.

Related peptides

Or compare prices across all peptides.

Ready to compare Thymosin Alpha-1?

See prices across trusted, third-party-tested vendors, normalized per milligram.

Compare Thymosin Alpha-1 prices →